Health Press Release – Newsletter for January 18, 2011

MRC Technology Appoints New Director of Corporate Partnerships

LONDON, January 17, 2011 – MRC Technology announced today that Mike Johnson has been appointed
Director, Corporate Partnerships. Mike joins MRC Technology to act as the
principal conduit for communication between the UK's Medical Research Council
(MRC) and MRC Technology, and to build productive partnerships with
technology and funding organisations both nationally and internationally
while ensuring operational delivery of …. Original article on Gaea Times at  : MRC Technology Appoints New Director of Corporate Partnerships.

Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony

LONDON, January 17, 2011 – Chiltern International Limited (Chiltern), a global contract research
organization (CRO), announced that Chiltern has won multiple awards at the
PharmaTimes Annual Awards 2010 ceremony held at the Park Plaza Riverbank
Hotel in London. The competition, established in 1999, celebrates the
competence and ability of top clinical research professionals.

Glenn Kerkhof, …. Original article  : Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony.

Astellas Enters Into License Agreement With TOLMAR

Expansion of Territory for Eligard(R) in Asia, Middle East, Africa and CIS
TOKYO, January 17, 2011 – Astellas Pharma Inc. (TSE:4503"Astellas") announced today that its
European subsidiary Astellas Pharma Europe Ltd.("Astellas Pharma Europe",
headquarters: Stains, U.K.)" acquired the license for commercialization of
the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc.
("TOLMAR", headquarters: Colorado, U.S.A.) on December 22, … Read this article on Gaea Times at : Astellas Enters Into License Agreement With TOLMAR.

Final NICE Appraisal Recommends Improved Access to Treatment and Care of People With Early Alzheimer’s Disease

New Survey Shows More Than Half (57.9%) of GPs Likely to Recall Mild Alzheimer's Patients Previously Denied Treatment for Reassessment

LONDON, January 18, 2011 – The National Institute for Health and Clinical Excellence (NICE) today
published its final appraisal determination containing final recommendations
on the use of specific treatments for Alzheimer's disease. The new ruling
means Alzheimer's patients …. Source  : Final NICE Appraisal Recommends Improved Access to Treatment and Care of People With Early Alzheimer's Disease.